Lupus & antiphospholipid syndrome
Patients with laboratory criteria of anti-phospholipid syndrome and ‘non-criteria’ manifestations: a multicenter cohort
Main finding · ThrombocytopeniaResult — go to the resultOdds ratio 3.6 95% CI 1.7–7.6Authors' conclusion
'Clinical non-criteria' patients displayed significant treatment use, predominantly haematological involvement, and less severe manifestations than definite APS controls.
Study context
- Population
- Individuals fulfilling anti-phospholipid syndrome (APS) laboratory criteria in two tertiary European hospitals, 2005–2020
- Exposure
- Clinical non-criteria APS vs age-/gender-matched definite APS controls
- Clinical non-criterian = 75
- Outcome
- Thrombocytopenia
Methodological detailsmulticentre, age-/gender-matched controls
- Multicentre
- Age-/gender-matched controls
Main finding
As reported in the abstract
Odds ratio
3.6
95% CI 1.7–7.6
P = 0.001
Clinical non-criteriavs Definite APS
OR 3.6 (95% CI 1.7–7.6); P = 0.001
Observational data: associations, not effects.
Further findings
| Outcome | P value |
|---|---|
| Valvular heart diseaseDefinite APS vs Clinical non-criteria · occurred only in definite APS | P < 0.001 |
Valvular heart disease
- Livedoid vasculopathy, seizures, chorea, transverse myelitis, bone necrosis and alveolar haemorrhage occurred only in definite APS
GC use in patients with thrombocytopenia
- Corticosteroids required
- 40%
Suspected progression to systemic lupus erythematosus (SLE) in non-SLE individuals
- Suspicion of progression towards SLE
- 19%
Manifestations in anticoagulated patients
- White-matter lesions, nephropathy, superficial vein thrombosis, amaurosis fugax and livedoid vasculopathy
Original publication
Patients with laboratory criteria of anti-phospholipid syndrome and ‘non-criteria’ manifestations: a multicenter cohort. Scand J Rheumatol. Published 20 June 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →